FindTrial
Sign In

TDF Placebo

DRUG10 trials

Sponsors

Gilead Sciences

Conditions

Chronic HBV InfectionChronic Hepatitis BHBVHBeAg-negative Chronic Hepatitis BHBeAg-positive Chronic Hepatitis BHepatitis B

Phase 2

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.
CompletedNCT00298363
Gilead SciencesChronic Hepatitis B
Start: 2006-04-30End: 2011-04-30Updated: 2013-04-25

Phase 3

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B
CompletedNCT00116805
Gilead SciencesChronic Hepatitis B
Start: 2005-06-30End: 2016-01-31Updated: 2017-03-09
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
CompletedNCT00117676
Gilead SciencesChronic Hepatitis B
Start: 2005-02-28End: 2016-01-31Updated: 2017-03-07
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
CompletedNCT00737568
Gilead SciencesHepatitis B
Start: 2008-09-30End: 2015-02-28Updated: 2016-03-11
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
Active, not recruitingNCT01651403
Gilead SciencesChronic Hepatitis B
Start: 2012-12-06End: 2027-07-01Updated: 2026-01-30
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
CompletedNCT01940471
Gilead SciencesHBeAg-positive Chronic Hepatitis B
Start: 2013-09-11End: 2022-10-13Updated: 2023-10-10
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
CompletedNCT01940341
Gilead SciencesHBeAg-negative Chronic Hepatitis B
Start: 2013-09-12End: 2022-08-31Updated: 2023-09-25
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)
CompletedNCT02836236
Gilead SciencesChronic HBV Infection, HBV
Start: 2015-06-19End: 2023-09-18Updated: 2024-10-02
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
CompletedNCT02836249
Gilead SciencesChronic HBV Infection, HBV
Start: 2015-06-19End: 2023-08-31Updated: 2024-10-15
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
CompletedNCT02979613
Gilead SciencesChronic Hepatitis B
Start: 2016-12-29End: 2020-01-30Updated: 2020-09-14

Related Papers

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Alimentary Pharmacology & Therapeutics2024-09-2719 citations
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.
2024-08-0728 citations
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
JHEP Reports2023-07-1319 citations
3-year Treatment of Tenofovir Alafenamide <i>vs</i>. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China.
2021-04-2825 citations
S1070 A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results
The American Journal of Gastroenterology2020-10-011 citations
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
2020-02-2093 citations
Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Liver International2019-05-28151 citations
Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
2019-02-2022 citations
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
2018-09-2437 citations
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.
2018-06-2024 citations
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
2018-01-17284 citations
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
2017-02-1217 citations
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
2016-09-22341 citations
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
2016-09-22328 citations
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Journal of Hepatology2016-08-2260 citations
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B
Gut2016-08-1762 citations
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
2014-06-1130 citations
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
2013-12-22114 citations
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
2012-12-101322 citations
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
2008-12-01810 citations